ISHLT慢性肺移植物功能障碍共识标准适用于肺慢性移植物抗宿主病
本研究将2019年ISHLT慢性肺移植物功能障碍(CLAD)标准改编用于定义肺慢性移植物抗宿主病(PcGVHD)新表型,并在166例(47.4%)符合改编标准的患者中比较其与NIH标准的识别效能。改编标准识别出阻塞性、限制性、混合型和未定义4种表型,其中88例未达NIH的BOS标准者死亡风险仍升高(HR=1.88,95%CI 1.20-2.95,P=.006)。
要点
- 改编的ISHLT CLAD标准可识别NIH标准漏诊的高危PcGVHD患者
- 符合改编标准但未达NIH BOS标准者死亡风险升高(HR=1.88)
- 改编标准有望成为肺cGVHD表型分型与研究的工具
核心结论
- 改编标准在识别被NIH标准漏诊的高危PcGVHD患者方面具有潜力。
- 改编标准可能成为更好地对cGVHD肺部疾病进行表型分型与研究的工具。
研究设计与样本
- 研究回顾了cGVHD自然病史方案(#NCT00092235)中的连续患者,并将2019年ISHLT CLAD标准改编用于定义PcGVHD。
- 改编标准将PcGVHD定义为造血干细胞移植后第1秒用力呼气容积低于预测值的80%,分为阻塞性、限制性、混合阻塞/限制性和未定义4种表型。
- 由独立裁定委员会对受试者进行诊断和表型判定。
主要发现
- 166例(47.4%)患者符合改编标准,包括阻塞性12例(3.4%)、限制性67例(19.1%)、混合阻塞/限制性47例(13.4%)和未定义40例(11.4%)。
- 符合改编标准的患者中,仅78例(不足一半)符合NIH的BOS标准(NIH+),其余88例不符合(NIH-)。
- NIH-受试者较无PcGVHD者死亡风险升高(风险比=1.88,95%置信区间=1.20-2.95;P=.006),且与NIH+受试者相似(P=.678)。
关键数值与推荐
- 改编标准定义PcGVHD为造血干细胞移植后第1秒用力呼气容积低于预测值的80%。
- 改编标准分为阻塞性、限制性、混合阻塞/限制性和未定义4种表型。
- 符合改编标准者166例(47.4%),其中阻塞性12例(3.4%)、限制性67例(19.1%)、混合阻塞/限制性47例(13.4%)、未定义40例(11.4%)。
- 符合改编标准者中NIH+ 78例,NIH- 88例。
- NIH-者较无PcGVHD者死亡风险比=1.88(95%置信区间=1.20-2.95;P=.006),与NIH+者相比P=.678。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary chronic graft-versus-host disease (PcGVHD) is a devastating complication of allogeneic hematopoietic stem cell transplant (HCT). The 2014 National Institutes of Health cGVHD consensus criteria (NIH criteria) only captures bronchiolitis obliterans syndrome (BOS). In this study, we adapted the 2019 International Society for Heart and Lung Transplantation (ISHLT) criteria of chronic lung allograft dysfunction (CLAD) to define novel phenotypes of PcGVHD and compared the performance of this criteria with the NIH criteria to identify patients with high-risk PcGVHD. We reviewed consecutive patients in a cGVHD natural history protocol (#NCT00092235) and adapted the 2019 CLAD criteria (the adapted criteria) to define PcGVHD as post-HCT forced expiratory volume at 1 second < 80% predicted value, with 4 phenotypes: obstructive, restrictive, mixed obstructive/restrictive, and undefined. An independent adjudication committee evaluated subjects for diagnosis and phenotyping. We identified 166 (47.4%) patients who met the adapted criteria, including obstruction (n = 12, 3.4%), restriction (n = 67, 19.1%), mixed obstruction/restriction (n = 47, 13.4%), and undefined (n = 40, 11.4%). In these patients, less than half (n = 78) met the NIH criteria for BOS (NIH+); the rest (n = 88) did not (NIH-). The NIH- subjects showed increased risk of death compared with those without PcGVHD (hazard ratio = 1.88, 95% confidence interval = 1.20-2.95; P = .006) that was similar to NIH+ subjects (P = .678). Our study demonstrated the potential of the adapted criteria in identifying patients with high-risk PcGVHD that have been missed by the NIH criteria. The adapted criteria could become a valuable tool to better phenotype and study lung disease in cGVHD.
引用
- Pang Y, Charya AV, Keller MB, et al. The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease. Blood Adv. 2022. PMID: 35522969. doi:10.1182/bloodadvances.2021006885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。